EOLS - Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker | Benzinga
Tuesday, Evolus Inc (NASDAQ:EOLS) released preliminary fourth quarter 2023 revenue of approximately $61 million, up 40% Y/Y -and a 22% increase sequentially versus the consensus of $56.97 million, driven primarily by higher volumes from market share gains.
Total net revenues for full-year 2023 were approximately $202 million, up 36% Y/Y and above the company’s guidance of $194 million-$198 million and the consensus of $198.03 million, according to data from Benzinga Pro.
Also Read: Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings.
For the fiscal year 2024, the aesthetics company expects revenues of $255 million-$265 million, up 26%-31% Y/Y, versus consensus of $264.44 million.
Evolus expects non-GAAP operating income to be positive in 2025 and continues ...